Overview

Hexagon Bio discovers and develops new medicines using synthetic biology and data science by analyzing genomic data from various species. Their proprietary algorithm identifies small molecule inhibitors that target proteins involved in diseases like cancer, and their synthetic biology platform allows for rapid production of these compounds for clinical development. Unlike competitors, Hexagon Bio focuses on early-stage drug candidates, licensing them to larger pharmaceutical companies for further development. The company's goal is to create effective treatments for complex diseases that existing therapies have difficulty addressing.

Simplify's Take

What believers are saying

• Raised $77.3 million in Series B financing to expand their discovery platform.
• Leverages reduced DNA sequencing costs to access vast genomic data.
• Partnerships in AI and machine learning enhance drug discovery efficiency.

What critics are saying

• Faces competition from biotech companies like Insitro and Recursion Pharmaceuticals.
• Requires continuous updates to their platform due to rapid technological advancements.
• Relies on external funding, posing financial risks if future funding is scarce.

What makes Hexagon Bio unique

• Hexagon Bio uses synthetic biology to discover drugs from fungal genomes.
• Their proprietary platform combines data science and synthetic biology for drug discovery.
• Hexagon Bio's team includes experts in computational biology, biochemistry, and software engineering.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$183.6M

Above

Industry Average

Funded Over

4 Rounds

Notable Investors:

SoftBank

Notable Investors:

SoftBank

$67,300,000

Late VC

Oct 2022

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!

Late VC Funding Comparison

Coming Soon

View all funding stages